Findings from this study point to the therapeutic potential of targeting the NPM1/c-Myc axis in BRAF-mutated colon cancer and provide a framework to devise novel strategies for counteracting the resistance to BRAF inhibition in colon cancer. The gene discussed is NPM1; the disease is malignant colon neoplasm.